Organon OGN Business Segments
| Q1 '26 | Q4 '25 | Q3 '25 | Q2 '25 | Q1 '25 | ||
|---|---|---|---|---|---|---|
| Revenue by Product | ||||||
| Arcoxia | $59M-4.8% | $70M+18.6% | $71M+2.9% | $63M-7.4% | $62M-17.3% | |
| Atozet | $85M+10.4% | $67M-13.0% | $95M-24.0% | $86M-38.6% | $77M-41.7% | |
| Brenzys | $20M+42.9% | $21M+50.0% | $23M-14.8% | $22M+83.3% | $14M-41.7% | |
| Clarinex | $31M-8.8% | $30M+11.1% | $25M-7.4% | $34M-2.9% | $34M-8.1% | |
| Cozaar/Hyzaar | $57M+3.6% | $53M-7.0% | $55M-6.8% | $56M-6.7% | $55M-17.9% | |
| Diprospan | $35M+16.7% | $38M+2.7% | $41M+10.8% | $41M+10.8% | $30M+3.4% | |
| Dulera | $35M-18.6% | $35M-32.7% | $34M-29.2% | $41M-12.8% | $43M-23.2% | |
| Emgality | $54M+68.8% | $49M+28.9% | $51M+75.9% | $42M+40.0% | $32M+220% | |
| Follistim AQ | $61M-11.6% | $58M-12.1% | $64M+1.6% | $74M+19.4% | $69M+50.0% | |
| Fosamax | $29M-12.1% | $36M-7.7% | $40M+5.3% | $34M-2.9% | $33M-17.5% | |
| Ganirelix Acetate Injection | $26M-3.7% | $24M-11.1% | $22M-15.4% | $27M0.0% | $27M-6.9% | |
| Hadlima | $67M+42.6% | $69M+56.8% | $63M+57.5% | $50M+78.6% | $47M+56.7% | |
| Jada | $5M-66.7% | $20M+11.1% | $20M+25.0% | $18M+28.6% | $15M+15.4% | |
| Marvelon/Mercilon | $26M-33.3% | $24M-22.6% | $31M+6.9% | $33M-19.5% | $39M+18.2% | |
| Nasonex | $65M-9.7% | $65M-14.5% | $60M-4.8% | $66M+10.0% | $72M-6.5% | |
| Nexplanon/Implanon NXT | $201M-19.0% | $210M-18.9% | $223M-8.2% | $240M-0.8% | $248M+12.7% | |
| NuvaRing | $24M+9.1% | $16M-36.0% | $26M+13.0% | $28M-3.4% | $22M-42.1% | |
| Ontruzant | $5M-72.2% | $19M-44.1% | $31M+55.0% | $31M-35.4% | $18M-53.8% | |
| Other Biosimilars | $24M+380% | $11M+83.3% | $9M+28.6% | $8M— | $5M— | |
| Other Cardiovascular | $28M-6.7% | $28M-17.6% | $33M+13.8% | $34M+6.3% | $30M-21.1% | |
| Other Non-Opiod Pain, Bone and Dermatology | $68M0.0% | $72M+5.9% | $80M+8.1% | $80M+2.6% | $68M-5.6% | |
| Other Respiratory | $12M-7.7% | $12M-33.3% | $12M-14.3% | $14M+7.7% | $13M+44.4% | |
| Other | $87M+11.5% | $85M-2.3% | $88M+4.8% | $87M+20.8% | $78M-7.1% | |
| Other | $18M-18.2% | $15M-50.0% | $21M-19.2% | $23M-25.8% | $22M-24.1% | |
| Other Women's Health | $46M+7.0% | $46M+17.9% | $43M+7.5% | $42M+23.5% | $43M0.0% | |
| Propecia | $30M+15.4% | $28M-12.5% | $33M+17.9% | $32M+14.3% | $26M+13.0% | |
| Proscar | $26M+8.3% | $24M+9.1% | $27M+17.4% | $22M-4.3% | $24M-7.7% | |
| Renflexis | $57M0.0% | $61M-4.7% | $70M-2.8% | $63M-8.7% | $57M-17.4% | |
| Rosuzet | $6M+50.0% | $8M-38.5% | $6M-45.5% | $6M-33.3% | $4M-75.0% | |
| Singulair | $40M-45.9% | $59M-29.8% | $53M-37.6% | $66M-29.0% | $74M-24.5% | |
| Vtama | $25M+4.2% | $39M+225% | $34M— | $31M— | $24M— | |
| Vytorin | $21M-8.7% | $25M-3.8% | $25M-3.8% | $27M-3.6% | $23M-17.9% | |
| Zetia | $87M+2.4% | $90M+16.9% | $93M+14.8% | $74M-1.3% | $85M+1.2% | |
| Number of pending claims by Product | ||||||
| Fosamax | $1.48K-14.8% | $1.52K-12.6% | $1.53K-50.3% | $1.71K-45.0% | $1.74K-44.3% | |
| Nexplanon/Implanon NXT | $190.0% | $17-15.0% | $17-19.0% | $18-14.3% | $19-5.0% | |
| Revenue by Geography | ||||||
| Asia Pacific and Japan | $226M-10.0% | $248M+1.6% | $251M-3.5% | $250M-3.8% | $251M-12.5% | |
| China | $194M-4.9% | $202M-5.2% | $219M+3.3% | $204M-5.6% | $204M-1.0% | |
| Europe and Canada | $412M+9.6% | $406M-3.3% | $417M-4.4% | $419M-8.3% | $376M-16.4% | |
| Latin America, Middle East, Russia, and Africa | $247M+2.9% | $262M-1.5% | $286M+17.7% | $285M+13.5% | $240M-12.4% | |
| Other | $23M-23.3% | $17M-48.5% | $23M-30.3% | $22M-37.1% | $30M-11.8% | |
| U.S. | $358M-13.1% | $372M-10.6% | $406M+2.0% | $414M+6.7% | $412M+11.1% |
Chart any of these lines over time, or line them up against competitors.
Compare these in charts →Questions, answered.
- How does Organon break its business down?
- Organon (OGN) reports revenue by product across 33 parts — Arcoxia, Atozet, Brenzys, Clarinex and Cozaar/Hyzaar. Each is extracted from the segment footnotes and tracked over time.
- Where does Organon's segment data come from?
- Segment breakdowns are pulled from the segment footnotes in Organon's SEC filings (the XBRL dimensional tags), so every line ties back to a reported figure. Switch between quarterly, annual, and TTM, or open any segment for its full history.